Compounds > (e)-4-hydroxy-3-methylbut-2-enyl-diphosphate

(e)-4-hydroxy-3-methylbut-2-enyl-diphosphate and Urinary-Bladder-Neoplasms

(e)-4-hydroxy-3-methylbut-2-enyl-diphosphate has been researched along with Urinary-Bladder-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for (e)-4-hydroxy-3-methylbut-2-enyl-diphosphate and Urinary-Bladder-Neoplasms

Article	Year
Synthesis and Biological Evaluation of ( E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses. Journal of medicinal chemistry, 2018, 03-08, Volume: 61, Issue:5 The aryloxy triester phosphoramidate prodrug approach has been used with success in drug discovery. Herein, we describe the first application of this prodrug technology to the monophosphate derivative of the phosphoantigen HMBPP and one of its analogues. Some of these prodrugs exhibited specific and potent activation of Vγ9/Vδ2 T-cells, which were then able to lyse bladder cancer cells in vitro. This work highlights the promise of this prodrug technology in the discovery of novel immunotherapeutics. Topics: Amides; Cells, Cultured; Humans; Immunotherapy; Lymphocyte Activation; Organophosphates; Phosphoric Acids; Prodrugs; Receptors, Antigen, T-Cell, gamma-delta; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Urinary Bladder Neoplasms	2018

Article

Year

Synthesis and Biological Evaluation of ( E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses.

Journal of medicinal chemistry, 2018, 03-08, Volume: 61, Issue:5

The aryloxy triester phosphoramidate prodrug approach has been used with success in drug discovery. Herein, we describe the first application of this prodrug technology to the monophosphate derivative of the phosphoantigen HMBPP and one of its analogues. Some of these prodrugs exhibited specific and potent activation of Vγ9/Vδ2 T-cells, which were then able to lyse bladder cancer cells in vitro. This work highlights the promise of this prodrug technology in the discovery of novel immunotherapeutics.

Topics: Amides; Cells, Cultured; Humans; Immunotherapy; Lymphocyte Activation; Organophosphates; Phosphoric Acids; Prodrugs; Receptors, Antigen, T-Cell, gamma-delta; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Urinary Bladder Neoplasms

2018